Iconovo (ICO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Iconovo (ICO) has a cash flow conversion efficiency ratio of -0.035x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-5.48 Million ≈ $-589.95K USD) by net assets (Skr157.77 Million ≈ $16.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Iconovo liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Iconovo - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how Iconovo's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Iconovo Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Iconovo ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Boa Concept SA
PA:ALBOA
|
0.010x |
|
Astute Metals NL
AU:ASE
|
-0.011x |
|
Phio Pharmaceuticals Corp
NASDAQ:PHIO
|
-0.243x |
|
Lunai Bioworks Inc.
NASDAQ:LNAI
|
0.079x |
|
SSH Group Ltd
AU:SSH
|
0.196x |
|
HF Company SA
PA:ALHF
|
0.038x |
|
Kalo Gold Corp
NASDAQ:KLGDD
|
-2.311x |
|
Hindcon Chemicals Limited
NSE:HINDCON
|
0.047x |
Annual Cash Flow Conversion Efficiency for Iconovo (2016–2025)
The table below shows the annual cash flow conversion efficiency of Iconovo from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see ICO stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | Skr117.92 Million ≈ $12.69 Million |
Skr-31.87 Million ≈ $-3.43 Million |
-0.270x | -42.31% |
| 2024-12-31 | Skr129.21 Million ≈ $13.91 Million |
Skr-24.54 Million ≈ $-2.64 Million |
-0.190x | +44.15% |
| 2023-12-31 | Skr113.53 Million ≈ $12.22 Million |
Skr-38.60 Million ≈ $-4.15 Million |
-0.340x | +30.53% |
| 2022-12-31 | Skr89.29 Million ≈ $9.61 Million |
Skr-43.70 Million ≈ $-4.70 Million |
-0.489x | -509.02% |
| 2021-12-31 | Skr137.03 Million ≈ $14.75 Million |
Skr-11.01 Million ≈ $-1.19 Million |
-0.080x | +53.31% |
| 2020-12-31 | Skr92.73 Million ≈ $9.98 Million |
Skr-15.96 Million ≈ $-1.72 Million |
-0.172x | -54.97% |
| 2019-12-31 | Skr108.79 Million ≈ $11.71 Million |
Skr-12.08 Million ≈ $-1.30 Million |
-0.111x | -599.12% |
| 2018-12-31 | Skr63.99 Million ≈ $6.89 Million |
Skr-1.02 Million ≈ $-109.38K |
-0.016x | +86.88% |
| 2017-12-31 | Skr31.52 Million ≈ $3.39 Million |
Skr-3.82 Million ≈ $-410.77K |
-0.121x | -117.56% |
| 2016-12-31 | Skr8.73 Million ≈ $939.49K |
Skr6.02 Million ≈ $647.74K |
0.689x | -- |
About Iconovo
Iconovo AB (publ) develops inhaled medicinal products in Sweden. The company offers ICOres, a multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; and ICOone nasal single-dose dry powder inhaler for nasal use. It serves generic companies. The company has a collaboration agreeme… Read more